Alio and Lifeline create partnership for dialysis access patient monitoring

208

Alio has announced a partnership with Lifeline Vascular Care in support of patients living with end-stage renal disease (ESRD). Alio leverages artificial intelligence (AI) and the company’s SmartPatch sensor technology to non-invasively monitor vascular access health and other chronic conditions faced by ESRD patients. The partnership facilitates Lifeline’s collaboration in several different capacities: as a clinical trial partner, as a purchaser of the Alio remote monitoring system, and as an active participant in value-based care arrangements.   

Key partnership metrics are based on the improvement of quality of life and the overall patient care experience. Alio’s SmartPatch technology is expected to reduce potential complications and improve dialysis care team efficiency. 

Lifeline owns, manages, and operates a network of approximately 40 outpatient surgical centers, which, since inception have performed over 1.5 million patient encounters in the treatment of dialysis vascular access management and peripheral arterial disease (PAD). Their network consists of office-based labs and ambulatory surgical centers across the USA. 

Barry Brostoff, vice president of strategy & business development at Lifeline Vascular Care, commented: “We believe Alio’s innovative technology has the potential to provide our nephrologists with a tremendous opportunity to remotely monitor, analyse patient-specific data, and direct needed interventions earlier, supporting better patient outcomes and an overall lower cost to the system. We are proud to have collaborated with Alio’s team to conduct clinical trial studies at our Cincinnati center with Antoine Samaha (director of the Dialysis Access Center of Cincinnati, Cincinnati, USA) and look forward to another trial in our Huntsville joint venture, North Alabama Vascular and Dialysis Care, with John Clark of Nephrology Consultants of Alabama (Huntsville, USA), before the end of the year.”  

Upon US Food and Drug Administration (FDA) approval of the Alio remote monitoring system, Lifeline plans to include SmartPatch products in its formulary, allowing its network of clients to utilise on a fee-for-service basis. Lifeline will work with Alio to facilitate the implementation of value-based care arrangements with centers within their network, with the objective of providing an economic arrangement beneficial to all parties. Overall, the partnership with Alio and Lifeline will support Alio’s growth objectives and its overarching goal of improving patient outcomes by enabling physicians to deliver the best patient care possible. 

LEAVE A REPLY

Please enter your comment!
Please enter your name here